河南新天地药业

Henan Xintiandi Pharmaceutical is a prominent Chinese manufacturer specializing in pharmaceutical intermediates and active pharmaceutical ingredients (APIs). The company is a leading global producer of D-p-hydroxyphenylglycine and its derivatives, which are essential building blocks for semi-synthetic penicillin and cephalosporin antibiotics. Listed on the Shenzhen Stock Exchange, Xintiandi Pharmaceutical leverages advanced chemical synthesis and enzymatic technologies to supply major pharmaceutical firms worldwide. Their core business supports the production of high-volume anti-infectives, including amoxicillin, cefadroxil, and cefprozil. In addition to its intermediate business, the company is expanding its capabilities into downstream API production and finished dosage forms to enhance its value chain.